Carbidopa

FDA approves ONGENTYS® ▼ (opicapone)

Wednesday, April 29, 2020 - 8:00am

BIAL announced today that the U.S Food and Drug Administration (FDA) has approved ONGENTYS (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinsons disease experiencing off episodes.

Key Points: 
  • BIAL announced today that the U.S Food and Drug Administration (FDA) has approved ONGENTYS (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinsons disease experiencing off episodes.
  • This approval is a landmark in BIALs ongoing commitment to the quality of life of Parkinsons patients and their caregivers.
  • We look forward to working with our partner in the U.S., Neurocrine Biosciences, to make this therapy available to patients.
  • The FDA approval of opicapone is supported by data from 38 clinical studies, including two multinational Phase III clinical studies (BIPARK-1 and BIPARK-2).

Acorda Therapeutics to Present at Cowen Annual Health Care Conference

Monday, February 24, 2020 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Cowen and Company Annual Health Care Conference on Monday, March 2 at 2:50PM EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Cowen and Company Annual Health Care Conference on Monday, March 2 at 2:50PM EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Acorda to Present Data at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

Wednesday, February 12, 2020 - 12:00pm

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinsons Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinsons Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.
  • As Parkinsons progresses, people are likely to experience OFF periods, which are characterized by the return of Parkinsons symptoms, which can occur despite underlying baseline therapy.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
  • INBRIJA is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.

Acorda to Present at the 38th Annual J.P. Morgan Healthcare Conference

Wednesday, January 8, 2020 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 9:30am PST / 12:30pm EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 9:30am PST / 12:30pm EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes

Monday, October 14, 2019 - 11:47pm

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.

Key Points: 
  • Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • To help patients with questions about access to NOURIANZ, Kyowa Kirin offers the Kyowa Kirin Cares program.
  • NOURIANZ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Acorda Therapeutics to Present at the 2019 Cantor Healthcare Conference

Wednesday, September 25, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Acorda to Present Data at the International Congress of Parkinson’s Disease and Movement Disorders

Wednesday, September 18, 2019 - 12:00pm

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data at the International Congress of Parkinsons Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data at the International Congress of Parkinsons Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.
  • Fox Foundation Industry Advisory Board and contributed to the design of and provided funding for the Financial and Social Impact of Parkinsons Disease Survey.
  • Results of the survey were also presented at the 5th World Parkinson Congress in June 2019.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.

Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease

Wednesday, August 28, 2019 - 2:34pm

Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.

Key Points: 
  • Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.
  • We are proud that NOURIANZ is now ready to help adult patients with Parkinsons disease in the US, said Tomohiro Sudo, Head of Global Product Management Office of Kyowa Kirin.
  • We are grateful for the FDA approval and for the many dedicated scientists and patients whose participation in our research programs has resulted in a new treatment option for Parkinson's disease.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders

Tuesday, June 25, 2019 - 12:00pm

JERUSALEM, June 25, 2019 /PRNewswire/ ---Intec Pharma Ltd.(NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients were published in the peer-reviewed journal, Parkinsonism and Related Disorders.

Key Points: 
  • JERUSALEM, June 25, 2019 /PRNewswire/ ---Intec Pharma Ltd.(NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients were published in the peer-reviewed journal, Parkinsonism and Related Disorders.
  • The article presents results from cohorts 1-4 out of the 6 cohorts of PD patients who participated in the study.
  • Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website.
  • Modi, Clinical pharmacokinetics of IPX066: evaluation of dose proportionality and effect of food in healthy volunteers, Clin.

Acorda Therapeutics to Present at Jefferies 2019 Healthcare Conference

Thursday, May 23, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in patients with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.